down arrow

Zoetis, Inc.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US98978V1035
USD
120.41
-2.16 (-1.76%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

119.72123.31

52 Week

115.25181.85
Valuation
Technical
Day's Volume

CASH

4.94 M

Shareholding (Mar 2025)

FII

31.06%

Held by 600 FIIs

DII

36.04%

Held by 80 DIIs

Promoter

0.01%

How big is Zoetis, Inc.?

22-Jun-2025

As of Jun 18, Zoetis, Inc. has a market capitalization of $76.59 billion, with net sales of $9.29 billion and net profit of $2.53 billion over the latest four quarters.

As of Jun 18, Zoetis, Inc. has a market capitalization of 76,587.16 million, categorizing it as a Large Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 9,286.00 million, while the sum of Net Profit for the same period is 2,528.00 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds of 4,770.00 million and Total Assets amounting to 14,237.00 million.

Read More

What does Zoetis, Inc. do?

22-Jun-2025

Zoetis, Inc. specializes in animal health medicines and vaccines, operating in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $2.22 billion and a market cap of approximately $76.59 billion.

Overview:<BR>Zoetis, Inc. is engaged in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines, operating within the Pharmaceuticals & Biotechnology industry and classified as a large-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 2,220 Million (Quarterly Results - Mar 2025)<BR>Most recent Net Profit: 631 Million (Quarterly Results - Mar 2025)<BR>Market-cap: USD 76,587.16 Million (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 31.00<BR>Dividend Yield: 82.27%<BR>Debt Equity: 1.04<BR>Return on Equity: 55.54%<BR>Price to Book: 16.45<BR><BR>Contact Details:<BR>Address: 10 Sylvan Way, PARSIPPANY NJ: 07054-3825<BR>Tel: 1 973 8227000<BR>Website: https://www.zoetis.com/

Read More

Who are in the management team of Zoetis, Inc.?

22-Jun-2025

As of March 2022, the management team of Zoetis, Inc. includes Non-Executive Chairman Michael McCallister, CEO Kristin Peck, and Directors Antoinette Leatherberry, Paul Bisaro, Frank D'Amelio, and Sanjay Khosla. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Zoetis, Inc. includes the following individuals:<BR><BR>- Mr. Michael McCallister, who serves as the Non-Executive Independent Chairman of the Board.<BR>- Ms. Kristin Peck, who is the Chief Executive Officer and a Director.<BR>- Ms. Antoinette Leatherberry, who is a Director.<BR>- Mr. Paul Bisaro, who is an Independent Director.<BR>- Mr. Frank D'Amelio, who is also an Independent Director.<BR>- Mr. Sanjay Khosla, who serves as an Independent Director.<BR><BR>This team plays a crucial role in overseeing the company's strategic direction and operations.

Read More

Is Zoetis, Inc. technically bullish or bearish?

29-Jun-2025

As of June 27, 2025, Zoetis, Inc. is in a bearish trend with moderate strength, indicated by daily moving averages and weekly Bollinger Bands, despite a mixed MACD signal.

As of 27 June 2025, the technical trend for Zoetis, Inc. has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include the daily moving averages indicating bearish momentum, and the weekly Bollinger Bands also confirming a bearish outlook. The MACD shows a mixed signal with a mildly bullish weekly reading but a bearish monthly perspective. Overall, the combination of these indicators suggests a prevailing bearish sentiment in the market for Zoetis, Inc.

Read More

Is Zoetis, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Zoetis, Inc. is fairly valued with a P/E ratio of 31, but has underperformed the S&P 500 with a year-to-date return of -11.58% compared to the index's 13.30%.

As of 17 October 2025, the valuation grade for Zoetis, Inc. moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 31, a Price to Book Value of 17.32, and an EV to EBITDA of 21.76. In comparison, Eli Lilly & Co. has a higher P/E of 40.89, while Johnson & Johnson shows a lower P/E of 26.18, indicating that Zoetis is positioned competitively within its peer group.<BR><BR>Despite the fair valuation, Zoetis has underperformed relative to the S&P 500, with a year-to-date return of -11.58% compared to the S&P 500's 13.30%. This trend continues over longer periods, with a 5-year return of -11.92% against the S&P 500's impressive 91.29%, suggesting that while the stock may be fairly valued, it faces significant challenges in generating returns compared to broader market benchmarks.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

High Management Efficiency with a high ROCE of 33.61%

 
2

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 1.22 times

 
3

Healthy long term growth as Net Sales has grown by an annual rate of 8.16%

 
4

The company has declared Positive results for the last 6 consecutive quarters

5

With ROCE of 36.14%, it has a fair valuation with a 8.99 Enterprise value to Capital Employed

6

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 71,581 Million (Large Cap)

stock-summary
P/E

31.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

60.56%

stock-summary
Debt Equity

1.03

stock-summary
Return on Equity

52.68%

stock-summary
Price to Book

14.38

Revenue and Profits:
Net Sales:
2,460 Million
(Quarterly Results - Jun 2025)
Net Profit:
718 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-21.4%
0%
-21.4%
6 Months
-28.58%
0%
-28.58%
1 Year
-31.32%
0%
-31.32%
2 Years
-33.88%
0%
-33.88%
3 Years
-23.51%
0%
-23.51%
4 Years
-46.08%
0%
-46.08%
5 Years
-23.77%
0%
-23.77%

Zoetis, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Zoetis, Inc. Stock Plummets to New 52-Week Low of $122.00

Zoetis, Inc. Stock Plummets to New 52-Week Low of $122.00

Zoetis, Inc. has reached a new 52-week low, reflecting a 30.4% decline over the past year, contrasting with the S&P 500's positive performance. The company, with a market cap of USD 71,581 million, features a P/E ratio of 31.00 and a dividend yield of 60.56%.

Read More

Is Zoetis, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Zoetis, Inc. moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 31, a Price to Book Value of 17.32, and an EV to EBITDA of 21.76. In comparison, Eli Lilly & Co. has a higher P/E of 40.89, while Johnson & Johnson shows a lower P/E of 26.18, indicating that Zoetis is positioned competitively within its peer group. Despite the fair valuation, Zoetis has underperformed relative to the S&P 500, with a year-to-date return of -11.58% compared to the S&P 500's 13.30%. This trend continues over longer periods, with a 5-year return of -11.92% against the S&P 500's impressive 91.29%, suggesting that while the stock may be fairly valued, it faces significant challenges in generating returns compared to broader market benchmarks....

Read More
Zoetis, Inc. Experiences Valuation Adjustment Amidst Competitive Market Landscape

Zoetis, Inc. Experiences Valuation Adjustment Amidst Competitive Market Landscape

Zoetis, Inc. has recently adjusted its valuation, with a current P/E ratio of 31 and strong financial metrics, including a return on capital employed of 36.14% and a return on equity of 55.54%. The company remains competitive within the Pharmaceuticals & Biotechnology sector despite recent performance challenges.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
8.16%
EBIT Growth (5y)
10.30%
EBIT to Interest (avg)
12.16
Debt to EBITDA (avg)
1.22
Net Debt to Equity (avg)
1.04
Sales to Capital Employed (avg)
0.77
Tax Ratio
20.90%
Dividend Payout Ratio
32.86%
Pledged Shares
0
Institutional Holding
98.14%
ROCE (avg)
33.61%
ROE (avg)
48.44%
Valuation key factors
Factor
Value
P/E Ratio
31
Industry P/E
Price to Book Value
17.32
EV to EBIT
24.87
EV to EBITDA
21.76
EV to Capital Employed
8.99
EV to Sales
9.20
PEG Ratio
3.69
Dividend Yield
78.17%
ROCE (Latest)
36.14%
ROE (Latest)
55.54%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 232 Schemes (32.83%)

Foreign Institutions

Held by 600 Foreign Institutions (31.06%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 10.81% vs -4.19% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 13.79% vs 8.61% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,460.00",
          "val2": "2,220.00",
          "chgp": "10.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,112.00",
          "val2": "965.00",
          "chgp": "15.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "58.00",
          "val2": "59.00",
          "chgp": "-1.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "25.00",
          "val2": "-11.00",
          "chgp": "327.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "718.00",
          "val2": "631.00",
          "chgp": "13.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "402.00%",
          "val2": "381.10%",
          "chgp": "2.09%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 8.33% vs 5.74% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 6.67% vs 10.85% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "9,256.00",
          "val2": "8,544.00",
          "chgp": "8.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3,889.00",
          "val2": "3,560.00",
          "chgp": "9.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "242.00",
          "val2": "258.00",
          "chgp": "-6.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-62.00",
          "val2": "-95.00",
          "chgp": "34.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2,496.00",
          "val2": "2,340.00",
          "chgp": "6.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "366.50%",
          "val2": "359.20%",
          "chgp": "0.73%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
2,460.00
2,220.00
10.81%
Operating Profit (PBDIT) excl Other Income
1,112.00
965.00
15.23%
Interest
58.00
59.00
-1.69%
Exceptional Items
25.00
-11.00
327.27%
Consolidate Net Profit
718.00
631.00
13.79%
Operating Profit Margin (Excl OI)
402.00%
381.10%
2.09%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 10.81% vs -4.19% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 13.79% vs 8.61% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
9,256.00
8,544.00
8.33%
Operating Profit (PBDIT) excl Other Income
3,889.00
3,560.00
9.24%
Interest
242.00
258.00
-6.20%
Exceptional Items
-62.00
-95.00
34.74%
Consolidate Net Profit
2,496.00
2,340.00
6.67%
Operating Profit Margin (Excl OI)
366.50%
359.20%
0.73%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 8.33% vs 5.74% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 6.67% vs 10.85% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Zoetis, Inc. stock-summary
stock-summary
Zoetis, Inc.
Pharmaceuticals & Biotechnology
Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.
Company Coordinates stock-summary
Company Details
10 Sylvan Way , PARSIPPANY NJ : 07054-3825
stock-summary
Tel: 1 973 8227000
stock-summary
https://www.zoetis.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."